A Randomized Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Patients With Metastatic Hormone Reseptor Positive Breast Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 22 Oct 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Cyclophosphamide; Cyclophosphamide; Doxorubicin liposomal
Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
Focus Adverse reactions; Therapeutic Use
Acronyms ICON; ICON CA209-9FN

06 Feb 2024 Status changed from active, no longer recruiting to completed.
13 Sep 2022 Results presented at the 47th European Society for Medical Oncology Congress
14 Jun 2022 Planned End Date changed from 1 Jan 2025 to 11 May 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com